Potential Post Market Gainer - Neurosense Therapeutics (NRSN) To Trade!
$Neurosense Therapeutics Ltd(NRSN)$ release a news that it will report New Data From Randomized, Placebo-Controlled, Double-Blind Segment Of Phase 2b PARADIGM ALS Trial On 05 Dec. My scanner has picked up this stock for some potential trading today (05 Dec). In this article, I would like to share on the technical indicators to show why this stock might be worth to look into. Technical Indicator - Simple Moving Average (SMA) NRSN has just crossed the 50-day period yesterday (04 Dec), with the anticipated release of its trial. I believe it should be staying above the 50-day period for a while. Technical Indicator - Average Directional Index (ADX) ADX is currently between 20 and 40, but there is an uptrend movement, +DI is above -DI suggesting a bull
First things first. They are going to need lots of money to do the Phase 2, and thenPhase 3 studies. Hundreds of millions. So either debt or equity offering or some kind of collaboration with big pharma, which would be smart. This company, with no revenue and $8 M in cash cannot do it by itself.$Neurosense Therapeutics Ltd(NRSN)$
Looking forward to seeing this tomorrow!Do the DD on CTMX, Millions upfront and then billions through royalties and milestone payments. Undervalued with lots of potential. GLTA!your continued support in liking and commenting on my posts really encouraged me a lot.❤️....$Neurosense Therapeutics Ltd(NRSN)$
3 Penny Stocks To Watch While The Stock Market Is Down
Even with the stock market down, it isn't all doom and gloom. In fact, as major indexes slip lower, there are more than a fewpenny stocksto watch right now. This seems to have become a trend for 2022 as cheap stocks remain a daily focus while broader trends send large- & mega-cap stocks to new lows.Are penny stocks risky? You bet and it's the high-risk, high-reward aspect that is so attractive to day traders in particular. Though investing in penny stocks may be an entirely different beast, during the 2022 stock market crash, the individual moves made by stocks under $5 are unavoidable. The critical part for market participants to bear in mind is that knowing how to trade is the most important thing to learn before diving into this volatile arena.Let's look at a handful
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
03-31
Annual Report
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]